Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

NEW YORK, Oct. 1 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

Intra-Cellular Therapies presented preclinical data at the 2nd World Parkinson Congress held in Glasgow, Scotland, demonstrating ITI-002 was effective in improving motor and non-motor behaviors relevant to the treatment of Parkinson's disease. In well-established pre-clinical models of PD, ITI-002 was shown to restore normal motor function when given in combination with L-DOPA; ITI-002 increased the effectiveness of a sub-threshold and a sub-maximal dose of L-DOPA when the compounds were co-administered in unilaterally 6-hydroxy dopamine-lesioned or reserpine-treated mice. This combination resulted in a full restoration of the affected limb use and a re-establishment of normal mobility. ITI-002 also reversed the akinesia and catalepsy induced by the dopamine receptor antagonist haloperidol. In other pre-clinical models, ITI-002 was shown to improve cognitive performance and to increase daytime wakefulness without causing psychomotor stimulation.

"We are pleased to have demonstrated the ability of ITI-002 to improve motor and non-motor behaviors in pre-clinical models relevant to Parkinson's disease. These data suggest ITI-002 may be useful in prolonging the effectiveness and lowering the doses of dopamine replacement therapies, thereby providing for full restoration of motor function without causing troubling side effects in patients with Parkinson's Disease," stated Sharon Mates, Chief Executive Officer of Intra-Cellular Therapies.  "Since ITI-002 acts by enhancing intra-cellular dopamine signaling, ITI-002 also may be useful as a stand-alone treatment early in this disease when residual dopamine is still present.  In addition, patients with Parkinson's disease often suffer co-mor
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in ... big ideas for 2014 in production and sales of ... produce high-quality, low-cost, DRM-free ebooks and to use the ... The first major development will be bookstore sales in ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... MONICA, Calif., Oct. 9 Aida,Pharmaceuticals, Inc. ... China,s,leading pharmaceutical companies, today announced that the ... sale of Etimicin,sulfate throughout China. Aida expects ... to increase noticeably as sales efforts are,pursued ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... company, today announced that it intends to ... Food and Drug Administration,(FDA) for its innovative, ... "After reviewing the data from our recently ...
... Pharmaceutical and biotech,companies reach much greater and sustained ... and marketing, balancing therapeutic,innovation with commercial focus in ... companies to break down the walls that have ... strengths of both,talented medical researchers and skillful marketers. ...
Cached Biology Technology:Sales of Etimicin Sulfate to Expand Nationwide as Government Restriction is Lifted 2Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 2Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 3Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 4Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 5Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 6Pharmaceutical Product Launch: Commercially Focused R&D Increases Drug's Market Potential 2
(Date:4/21/2014)... which is commonly used as a farm soil fertilizer, ... genes from the cows, gut bacteria. The findings, reported ... the American Society for Microbiology, hints that cow manure ... resistance genes that transfer to bacteria in the soils ... resistance (AR) genes have already been identified, but the ...
(Date:4/21/2014)... Dallas have received a federal grant to investigate ... of many everyday products might affect human health. ... and Dr. Rockford Draper, professor of molecular and ... from the National Institute of Environmental Health Sciences, ... track how multi-walled carbon nanotubes interact with human ...
(Date:4/21/2014)... Professor Lawrence Krauss was honored at the Academia ... to public understanding of science and for his ... The Academia Film Olomouc award for Outstanding Communication ... on April 19, in Olomouc, Czech Republic. , ... of science documentary films, and the largest such ...
Breaking Biology News(10 mins):Cow manure harbors diverse new antibiotic resistance genes 2Cow manure harbors diverse new antibiotic resistance genes 3Grant to fund research on possible cell contaminants 2Grant to fund research on possible cell contaminants 3Lawrence Krauss is honored at international festival of science documentary films 2Lawrence Krauss is honored at international festival of science documentary films 3
... (Edmonton) Two University of Alberta researchers have published a step ... harmful chemicals on commercial crops by developing plants that produce ... biologist Allen Good says the energy required to produce nitrogen ... a $100 billion a year. Good says that while they ...
... adelgid, has been marching north along the Appalachians, killing almost ... forests in Georgia, Tennessee, and Virginia. The pest recently arrived ... only extreme cold stops the adelgid. But now a ... "fungal microfactory" technology that promises to give forest managers and ...
... joint meeting of the International Ethological Conference (IEC) and ... more than 1,100 researchers from around the world for ... Included among the speakers will be one of ... head of the Department of Ethology at the Etvs ...
Cached Biology News:Forest fungus factory 2Behavior 2011 to draw global contingent of more than 1,100 animal researchers to IU next week 2